MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-c

Discovery

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) was identified in 2015 by Chang Lee, Pinchas Cohen, and colleagues working across the University of Southern California and the University of California Davis. The discovery was reported in the journal Cell Metabolism and represented a conceptual landmark: for the first time, a small peptide encoded entirely within mitochondrial DNA was shown to exert systemic, insulin-sensitising activity in living organisms [PMID:25738459].

Mitochondria retain a compressed, circular genome inherited maternally. That genome had long been considered to encode only the thirteen proteins of the oxidative phosphorylation machinery, alongside transfer and ribosomal RNAs. Lee, Cohen and colleagues recognised that short open reading frames within the 12S ribosomal RNA gene could, in principle, be translated into peptides. MOTS-c is the 16-amino-acid product of one such frame — a sequence (MRWQEMGYIFYPRKLR) that had previously been overlooked precisely because it lay within a region assumed to be non-coding for protein [PMID:25738459].

The initial paper demonstrated that MOTS-c is detectable in human plasma, that circulating levels correlate with metabolic health parameters, and that exogenous administration to high-fat-diet-fed mice reversed diet-induced obesity and restored insulin sensitivity without reducing food intake. These findings established MOTS-c as the founding member of a functional class now termed mitochondrial-derived peptides (MDPs), a group that also includes humanin and the SHLP series.

Mechanism of action

MOTS-c operates through several interconnected mechanisms that converge on cellular energy sensing and metabolic gene regulation.

AMPK activation independent of canonical upstream kinases. The dominant intracellular action of MOTS-c is activation of AMP-activated protein kinase (AMPK), the master energy sensor that governs glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and suppression of anabolic pathways under energy deficit. Crucially, MOTS-c achieves this without requiring liver kinase B1 (LKB1), the most important upstream AMPK kinase, and without relying on AICAR — the synthetic AMP-mimetic commonly used to activate AMPK experimentally [PMID:25738459]. This LKB1-independent route suggests MOTS-c interfaces with AMPK through a distinct, possibly direct mechanism that may be more selective in its downstream consequences than pharmacological AMPK activators.

Folate cycle and one-carbon metabolism modulation. One of the more mechanistically distinctive findings from the original Lee/Cohen work is that MOTS-c inhibits the folate cycle enzyme AICAR transformylase, leading to accumulation of endogenous AICAR within the cell. This metabolite then activates AMPK through the conventional AMP-mimicry pathway, creating a second, indirect route to AMPK activation that is spatially and temporally controlled by mitochondrial output [PMID:25738459]. The folate cycle sits at the intersection of nucleotide synthesis, methylation, and redox balance, which means MOTS-c exerts regulatory influence over pathways well beyond glucose metabolism.

Nuclear translocation under metabolic stress. Under conditions of glucose restriction or oxidative stress, MOTS-c undergoes translocation from the mitochondria to the nucleus — an uncommon behaviour for a mitochondrial product. Once in the nucleus, it regulates transcription through interaction with stress-response elements, modifying the expression of genes involved in antioxidant defence, inflammatory cytokine production, and mitochondrial biogenesis [PMID:29779023]. This retrograde mitochondria-to-nucleus signalling capacity positions MOTS-c as a genuine transcriptional mediator, not merely an enzyme activator.

Myofibre and insulin-signalling pathway regulation. At the level of skeletal muscle, MOTS-c enhances translocation of glucose transporter type four to the plasma membrane via AMPK-dependent mechanisms, increasing insulin-independent glucose uptake. In adipose tissue, it attenuates lipogenic gene expression. Together these peripheral actions produce the whole-body insulin-sensitising phenotype observed in the original mouse model [PMID:25738459].

Researched applications

Preclinical and observational human research has explored three principal areas of MOTS-c biology, each connecting to a different aspect of the peptide's mechanism.

High-fat-diet-induced metabolic dysfunction. The foundational mouse experiments from Lee and Cohen demonstrated that MOTS-c administration to animals maintained on a high-fat diet produced reductions in body weight, visceral adiposity, fasting insulin, and fasting glucose compared with vehicle-treated controls [PMID:25738459]. These effects occurred despite no measurable reduction in caloric intake, pointing to metabolic reprogramming rather than appetite suppression. AMPK activation in skeletal muscle and adipose tissue was confirmed as the proximate mechanism. Notably, MOTS-c administration also reversed established obesity when begun after animals had already gained weight, suggesting therapeutic as well as preventive potential in rodent models.

Exercise-mimetic gene expression. Reynolds, Wu, and collaborators published a Nature Communications study in 2021 demonstrating that circulating MOTS-c rises acutely in response to aerobic exercise in humans and mice, and that exogenous MOTS-c administration to aged sedentary mice produced a skeletal muscle transcriptomic profile closely resembling that induced by endurance training [PMID:33473141]. This included upregulation of genes governing mitochondrial biogenesis, oxidative substrate utilisation, and myofibre maintenance. The aged mice receiving MOTS-c showed improvements in treadmill endurance, grip strength, and mitochondrial respiratory capacity — effects that were substantially blunted when AMPK was pharmacologically inhibited, confirming the dependence of the exercise-mimetic phenotype on AMPK signalling [PMID:33473141]. The peptide has consequently attracted interest as a potential intervention for sarcopenia and age-related decline in physical performance.

Age-related decline and metabolic disease correlation. Cobb, Lee, and colleagues conducted a detailed analysis of MOTS-c plasma levels across age groups and metabolic phenotypes, finding that circulating concentrations decline progressively with age and are significantly lower in individuals with type two diabetes and obesity compared with age-matched metabolically healthy controls [PMID:32868851]. This age-dependent fall in MOTS-c correlates with increasing insulin resistance and inflammatory markers including interleukin-6 and tumour necrosis factor-alpha, raising the hypothesis that diminishing mitochondrial output of MOTS-c contributes causally to the metabolic deterioration of ageing. D'Souza and collaborators added a nuance to this picture by demonstrating that in healthy ageing men, skeletal muscle MOTS-c expression is associated with type I slow-twitch myofibre proportion — suggesting that the maintenance of oxidative muscle composition buffers the age-related decline in systemic MOTS-c availability [PMID:32197066].

Dosing range across published studies

No human clinical trials establishing safe or effective doses of MOTS-c have been completed and reported. All dosing information derives from preclinical animal studies or, in the case of human observations, from correlational biomarker measurements rather than interventional trials.

In mouse studies, intraperitoneal doses of five mg/kg per day produced the metabolic phenotype described in the original Cell Metabolism paper [PMID:25738459]. The Reynolds et al. treadmill study used subcutaneous delivery at comparable weight-adjusted amounts. Scaling these figures using body surface area conversion to approximate a human research benchmark produces an indicative range of approximately five to ten mg per administration, administered subcutaneously three times per week — the dosing schedule most commonly cited in researcher discussion forums and that appears in exploratory self-experimentation reports. Study durations in the published mouse literature range from two to eight weeks. There are no published dose-escalation safety studies in humans, and no established maximum tolerated dose.

Safety profile

MOTS-c has not undergone formal clinical safety evaluation. Within the preclinical literature, no acute or sub-chronic toxicity signals have been reported at the doses used in published experiments. Animals in multiple independent studies showed no adverse weight changes, haematological abnormalities, or organ pathology attributable to the peptide at research doses [PMID:25738459][PMID:33473141].

Because MOTS-c activates AMPK — a pathway with broad metabolic consequences — theoretical concerns include excessive reduction in blood glucose if combined with insulin secretagogues or exogenous insulin, and potential interference with mTOR-dependent anabolic signalling if administered in a peri-workout context. These theoretical interactions have not been formally studied. The peptide's nuclear translocation and gene-regulatory activity under stress conditions raises questions about long-term transcriptional effects that preclinical studies of standard duration cannot adequately address.

Local injection site reactions (transient erythema, mild induration) are the most commonly noted adverse events in self-report contexts and are consistent with the properties of subcutaneously administered peptides generally, rather than being specific to MOTS-c.

No human safety data from controlled trials exist. Researchers should apply standard precautions appropriate to any novel investigational compound.

UK regulatory status 2026

MOTS-c holds no Marketing Authorisation, Investigational Medicinal Product designation, or veterinary licence from the Medicines and Healthcare products Regulatory Agency (MHRA). As a mitochondrial-derived peptide with no approved clinical application anywhere in the world, it is classified as an unapproved research compound and cannot lawfully be sold, supplied, or administered to humans or animals for therapeutic purposes under the Human Medicines Regulations 2012.

In vitro laboratory research conducted within a controlled, accredited facility — where the compound is handled experimentally and not administered to humans — falls outside the scope of the Human Medicines Regulations. Researchers operating in such settings may obtain and handle MOTS-c as a research-grade chemical provided sourcing and usage comply with institutional governance requirements and the material is obtained from a supplier with appropriate documentation.

Researchers and clinicians considering any application beyond in vitro experimentation should seek legal and regulatory guidance specific to their jurisdiction and institutional framework before proceeding.

Reconstitution and storage

MOTS-c is supplied as a lyophilised white powder. Standard reconstitution uses bacteriostatic water (water for injection containing 0.9% benzyl alcohol), added slowly down the inner wall of the vial with the needle tip directed away from the lyophilised cake. The vial should be rolled or swirled gently — vigorous shaking is avoided to prevent peptide aggregation. A working concentration of one mg/mL is commonly used to give measurable injection volumes at research doses.

Reconstituted solution stored in a sealed, light-protected vial at two to eight degrees Celsius is considered stable for approximately four weeks. For longer archiving, single-use aliquots can be stored at minus twenty degrees Celsius; each aliquot should be thawed once and used immediately, as repeated freeze-thaw cycles increase the risk of structural degradation. Lyophilised powder kept desiccated, sealed, and away from direct light at below twenty-five degrees Celsius maintains manufacturer-stated integrity for up to twenty-four months. Reconstituted solution should be inspected for particulates or discolouration before use; any cloudy or discoloured preparation should be discarded.

Frequently asked research questions

How does MOTS-c differ from humanin? Both humanin and MOTS-c are mitochondrial-derived peptides encoded within the mitochondrial genome, but they arise from different regions and signal through different receptors. Humanin is encoded in the 16S rRNA gene and signals primarily through the tripartite receptor comprising CNTFR, WSX-1, and gp130, with pronounced cytoprotective and anti-apoptotic activity. MOTS-c is encoded in the 12S rRNA gene and acts primarily through AMPK-dependent metabolic reprogramming without a defined cell-surface receptor. The two MDPs have complementary but distinct activity profiles and are occasionally combined in longevity-oriented research stacks.

Is MOTS-c detectable in human blood naturally? Yes. Circulating MOTS-c has been measured by ELISA in multiple human cohorts. Plasma concentrations show substantial inter-individual variability and decline significantly with age and in the presence of metabolic disease, consistent with the hypothesis that reduced mitochondrial biosynthetic output underlies age-related metabolic fragility [PMID:32868851].

Does exercise increase endogenous MOTS-c? The Reynolds et al. Nature Communications paper confirmed that acute aerobic exercise transiently raises circulating MOTS-c in both young and older adults, with the magnitude of the increase correlating with exercise intensity [PMID:33473141]. This finding underpins the designation of MOTS-c as an exercise-induced mitokine and the interest in whether exogenous supplementation can replicate exercise-induced benefits in sedentary or mobility-limited individuals.

Can MOTS-c be combined with other metabolic peptides? Preclinical models have not systematically evaluated combination regimens. Self-experimentation reports most frequently pair MOTS-c with AOD-9604 for body composition purposes, or with humanin and epitalon in longevity protocols. No interaction data exist, and additive AMPK activation from combined agents is a theoretical consideration that has not been formally studied.

What distinguishes MOTS-c from pharmacological AMPK activators such as metformin? Metformin activates AMPK primarily through complex I inhibition and the resulting rise in the AMP-to-ATP ratio. MOTS-c reaches the same AMPK target through folate cycle modulation and LKB1-independent pathways, which may produce a more selective downstream signature [PMID:25738459]. Whether this mechanistic distinction translates to a meaningful clinical difference has not been tested in head-to-head studies.

---

MOTS-c appears in the following research stacks on this site: Epitalon + Humanin + MOTS-c Longevity Stack, MOTS-c + AOD-9604 Fat Loss Stack.

Source research-grade MOTS-c

MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-c is sold for laboratory and in vitro research use only. UK regulatory status: Unapproved research compound globally. Laboratory research use only..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk

References

Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.

1. Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3) :443-454 doi:10.1016/j.cmet.2015.02.009 · PMID: 25738459
2. Kim SJ, Mehta HH, Wan J, et al.. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging. 2018;10(6) :1239-1256 doi:10.18632/aging.101463 · PMID: 29779023
3. Reynolds JC, Bhatt DL, Wu LE, et al.. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1) :470 doi:10.1038/s41467-020-20790-0 · PMID: 33473141
4. Cobb LJ, Lee C, Xiao J, et al.. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Communications Biology. 2020;3(1) :475 doi:10.1038/s42003-020-01193-3 · PMID: 32868851
5. D'Souza RF, Woodhead JST, Zeng N, et al.. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging. 2020;12(6) :5260-5275 doi:10.18632/aging.102944 · PMID: 32197066